Experimental antibody ADG206 targets Hard-to-Treat cancers in first human trial
Disease control
Ongoing
This early-phase study tests a new drug called ADG206 in 14 people with advanced solid tumors that have not responded to standard treatments. ADG206 is an antibody designed to activate the immune system by targeting CD137, a protein on immune cells. The main goals are to check sa…
Phase: PHASE1 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC